Hyaluronic acid - Yooyoung Pharmaceutical
Alternative Names: YY 1201; YYD 302Latest Information Update: 09 Feb 2022
At a glance
- Originator Yooyoung Pharmaceutical
- Class Adjuvants; Antirheumatics; Eye disorder therapies; Glycosaminoglycans; Urologics
- Mechanism of Action Hyaluronic acid replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Osteoarthritis
Most Recent Events
- 09 Feb 2022 Preregistration for Osteoarthritis (In the elderly, In adults) in South Korea (Intra-articular), before February 2022 (Yooyoung Pharmaceutical pipeline, February 2022)
- 30 Mar 2021 No development reported - Phase-III for Osteoarthritis (In the elderly, In adults) in South Korea (Intra-articular)
- 15 Sep 2015 Investigation in Osteoarthritis in South Korea (Intra-articular)